• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在治疗期间，通过序列类型39的产KPC-2肺炎克雷伯菌中不同的基因组适应性变化出现了对头孢他啶-阿维巴坦的耐药性。

Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment.

作者信息

Galani Irene, Karaiskos Ilias, Angelidis Evdokia, Papoutsaki Vassiliki, Galani Lamprini, Souli Maria, Antoniadou Anastasia, Giamarellou Helen

机构信息

4th Department of Internal Medicine, Infectious Diseases Laboratory,Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

University General Hospital "ATTIKON", Rimini 1, 124 62, Chaidari, Greece.

出版信息

Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):219-224. doi: 10.1007/s10096-020-04000-9. Epub 2020 Jul 30.

DOI:10.1007/s10096-020-04000-9
PMID:32729059
Abstract

Three ceftazidime-avibactam-resistant KPC-2-producing Klebsiella pneumoniae strains of ST39 were isolated in Greece, from rectal swabs of three patients after 10-15 days of treatment. The patients were treated with ceftazidime-avibactam as monotherapy or in combination with colistin. Two of these strains harbored a D179Y or a D179V substitution in the Ω loop of KPC-2, corresponding to KPC-33, or to the novel KPC-57, respectively. The third strain had a 15 amino acid insertion after position 259 in the KPC-2, corresponding to KPC-44.

摘要

在希腊，从3例患者治疗10 - 15天后的直肠拭子中分离出3株产KPC - 2的肺炎克雷伯菌，它们对头孢他啶 - 阿维巴坦耐药，属于ST39型。这些患者接受了头孢他啶 - 阿维巴坦单药治疗或与黏菌素联合治疗。其中2株菌株在KPC - 2的Ω环中有D179Y或D179V替代，分别对应于KPC - 33或新型KPC - 57。第三株菌株在KPC - 2的259位之后有15个氨基酸插入，对应于KPC - 44。

相似文献

1
Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment.在治疗期间，通过序列类型39的产KPC-2肺炎克雷伯菌中不同的基因组适应性变化出现了对头孢他啶-阿维巴坦的耐药性。
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):219-224. doi: 10.1007/s10096-020-04000-9. Epub 2020 Jul 30.
2
In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies.产碳青霉烯酶肺炎克雷伯菌在接受头孢他啶/阿维巴坦治疗后体内出现头孢地尔和头孢他啶/阿维巴坦交叉耐药性。
Diagn Microbiol Infect Dis. 2024 Sep;110(1):116372. doi: 10.1016/j.diagmicrobio.2024.116372. Epub 2024 May 21.
3
Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.体内产 KPC-3 肺炎克雷伯菌出现对头孢他啶/阿维巴坦的耐药性。
J Antimicrob Chemother. 2019 Nov 1;74(11):3211-3216. doi: 10.1093/jac/dkz330.
4
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
5
Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.产碳青霉烯酶肺炎克雷伯菌引起的对头孢他啶/阿维巴坦耐药的血流感染：流行病学与基因组特征。
Clin Microbiol Infect. 2020 Apr;26(4):516.e1-516.e4. doi: 10.1016/j.cmi.2019.11.011. Epub 2019 Nov 16.
6
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
7
Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.产生赋予对头孢他啶-阿维巴坦耐药性的 KPC-2 突变的菌株中，沃博巴坦的效力比阿维巴坦的效力受影响更小。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.01936-19.
8
Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.产 KPC-23 肺炎克雷伯菌 ST258 临床分离株对头孢他啶-阿维巴坦耐药的基因组特征。
Clin Microbiol Infect. 2019 Jun;25(6):763.e5-763.e8. doi: 10.1016/j.cmi.2019.03.011. Epub 2019 Mar 28.
9
A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring Isolated in New York City.一株耐头孢他啶-阿维巴坦、碳青霉烯类敏感的肺炎克雷伯菌的分离与鉴定：来自纽约市的报告。
mSphere. 2020 Aug 26;5(4):e00775-20. doi: 10.1128/mSphere.00775-20.
10
Emergence of ceftazidime-avibactam-resistant during treatment, Finland, December 2018.2018 年 12 月，芬兰在治疗期间出现对头孢他啶-阿维巴坦耐药的 。
Euro Surveill. 2019 May;24(19). doi: 10.2807/1560-7917.ES.2019.24.19.1900256.

引用本文的文献

1
Diverse modes of ceftazidime/avibactam resistance acquisition in carbapenem-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa from a Chinese intensive care unit.来自中国重症监护病房的耐碳青霉烯类肺炎克雷伯菌和铜绿假单胞菌中获得头孢他啶/阿维巴坦耐药性的多种模式
Ann Clin Microbiol Antimicrob. 2025 May 30;24(1):35. doi: 10.1186/s12941-025-00800-z.
2
Global phylogeography and genetic characterization of carbapenem and ceftazidime-avibactam resistant KPC-33-producing Pseudomonas aeruginosa.产碳青霉烯酶和头孢他啶-阿维巴坦耐药的KPC-33铜绿假单胞菌的全球系统发育地理学和基因特征分析
NPJ Antimicrob Resist. 2025 Jan 7;3(1):3. doi: 10.1038/s44259-024-00073-0.
3

本文引用的文献

1
IS-Mediated Transfer of as the Main Route of Resistance Transmission During a Polyclonal, Multispecies Outbreak in a German Hospital.在德国一家医院的多克隆、多物种爆发期间，IS介导的[具体物质]转移作为耐药性传播的主要途径。 （注：原文中“of”后面似乎缺失关键信息）
Front Microbiol. 2019 Dec 17;10:2817. doi: 10.3389/fmicb.2019.02817. eCollection 2019.
2
Sequence type-258 carbapenem-resistant Klebsiella pneumoniae isolates in which ceftazidime-avibactam resistance emerged are not hypermutators.序列类型 258 型碳青霉烯类耐药肺炎克雷伯菌分离株中出现头孢他啶-阿维巴坦耐药性的并非高突变体。
Diagn Microbiol Infect Dis. 2020 Mar;96(3):114954. doi: 10.1016/j.diagmicrobio.2019.114954. Epub 2019 Nov 23.
3
Ceftazidime-avibactam tolerance and persistence among difficult-to-treat KPC-producing Klebsiella pneumoniae clinical isolates from bloodstream infections.
头孢他啶-阿维巴坦对血流感染中分离出的产KPC的难治疗肺炎克雷伯菌临床菌株的耐受性和持续性
Eur J Clin Microbiol Infect Dis. 2025 Feb;44(2):343-353. doi: 10.1007/s10096-024-05005-4. Epub 2024 Nov 30.
4
In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis.头孢他啶-阿维巴坦体外模拟体内 KPC 突变：表型、机制、酶水解的遗传结构和动力学。
Emerg Microbes Infect. 2024 Dec;13(1):2356146. doi: 10.1080/22221751.2024.2356146. Epub 2024 Jun 4.
5
Emergence and persistent spread of carbapenemase-producing high-risk clones in Greek hospitals, 2013 to 2022.2013 年至 2022 年期间，希腊医院中高产碳青霉烯酶高危克隆的出现和持续传播。
Euro Surveill. 2023 Nov;28(47). doi: 10.2807/1560-7917.ES.2023.28.47.2300571.
6
carbapenemase variants: the new threat to global public health.碳青霉烯酶变体：对全球公共健康的新威胁。
Clin Microbiol Rev. 2023 Dec 20;36(4):e0000823. doi: 10.1128/cmr.00008-23. Epub 2023 Nov 8.
7
Genomic analysis and antimicrobial activity of β-lactam/β-lactamase inhibitors and other agents against KPC-producing Klebsiella pneumoniae clinical isolates from Brazilian hospitals.巴西医院产 KPC 肺炎克雷伯菌临床分离株的β-内酰胺/β-内酰胺酶抑制剂和其他药物的基因组分析及抗菌活性
Sci Rep. 2023 Sep 5;13(1):14603. doi: 10.1038/s41598-023-41903-x.
8
Genetic Characterization of Carbapenem-Resistant Clinical Isolates in a Tertiary Hospital in Greece, 2018-2022.2018 - 2022年希腊一家三级医院耐碳青霉烯临床分离株的基因特征分析
Antibiotics (Basel). 2023 May 28;12(6):976. doi: 10.3390/antibiotics12060976.
9
The Effectiveness of Imipenem-Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase.亚胺培南-瑞来巴坦对KPC-2β-内酰胺酶的头孢他啶-阿维巴坦耐药变体的有效性
Antibiotics (Basel). 2023 May 11;12(5):892. doi: 10.3390/antibiotics12050892.
10
Identification of KPC-112 from an ST15 Klebsiella pneumoniae Strain Conferring Resistance to Ceftazidime-Avibactam.从一株对头孢他啶-阿维巴坦耐药的 ST15 肺炎克雷伯菌中鉴定出 KPC-112。
mSphere. 2022 Dec 21;7(6):e0048722. doi: 10.1128/msphere.00487-22. Epub 2022 Nov 14.
Improvement of the Immunochromatographic NG-Test Carba 5 Assay for the Detection of IMP Variants Previously Undetected.
改良免疫胶体金渗滤法 NG-Test Carba 5 检测试验，提高对先前未检测到的 IMP 变异体的检测能力。
Antimicrob Agents Chemother. 2019 Dec 20;64(1). doi: 10.1128/AAC.01940-19.
4
Whole-genome sequencing study of KPC-encoding Klebsiella pneumoniae isolated in Greek private laboratories from non-hospitalised patients.希腊私营实验室中非住院患者中产 KPC 编码肺炎克雷伯菌的全基因组测序研究。
J Glob Antimicrob Resist. 2020 Mar;20:78-81. doi: 10.1016/j.jgar.2019.07.027. Epub 2019 Aug 4.
5
Identification of L169P mutation in the omega loop of KPC-3 after a short course of ceftazidime/avibactam.在短疗程使用头孢他啶/阿维巴坦后，鉴定KPC-3的ω环中的L169P突变。
J Antimicrob Chemother. 2019 Aug 1;74(8):2466-2467. doi: 10.1093/jac/dkz201.
6
Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in -Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.携带blaKPC-2 的肺炎克雷伯菌序列型 307 分离株通过不同的基因组适应性连续出现头孢他啶-阿维巴坦耐药性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02101-17. Print 2018 Mar.
7
Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity.对头孢他啶-阿维巴坦的耐药性是由于产孔蛋白缺陷的肺炎克雷伯菌中 KPC 的转位和增加的外排活性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00989-17. Print 2017 Oct.
8
Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3.肺炎克雷伯菌中因孔蛋白突变和KPC-3表达增加导致对头孢他啶-阿维巴坦耐药
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00537-17. Print 2017 Jun.
9
Emergence of ST39 and ST656 extensively drug-resistant isolates in Wenzhou, China.中国温州出现ST39和ST656广泛耐药菌株。
Indian J Med Microbiol. 2017 Jan-Mar;35(1):145-146. doi: 10.4103/ijmm.IJMM_16_381.
10
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.